CenterBook Partners LP Buys Shares of 7,176 Abivax SA Sponsored ADR $ABVX

CenterBook Partners LP purchased a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 7,176 shares of the company’s stock, valued at approximately $968,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. WPG Advisers LLC raised its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Abivax in the 4th quarter valued at $67,000. Hantz Financial Services Inc. purchased a new stake in shares of Abivax during the 3rd quarter worth $52,000. Finally, Assetmark Inc. purchased a new stake in shares of Abivax during the fourth quarter valued at about $84,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Trading Down 4.6%

Shares of Abivax stock opened at $98.03 on Thursday. The firm’s 50 day simple moving average is $116.59 and its two-hundred day simple moving average is $119.41. The firm has a market capitalization of $7.81 billion, a price-to-earnings ratio of -18.82 and a beta of 0.69. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

Analysts Set New Price Targets

ABVX has been the subject of a number of analyst reports. Morgan Stanley decreased their target price on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, June 2nd. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Truist Financial decreased their price objective on Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and lowered their price objective for the stock from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Finally, Citizens Jmp upped their target price on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.